ACLXArcellx, Inc.
The Read
Arcellx’s stock surged about 11% on Q4 2025 earnings due to Gilead’s $115-per-share acquisition deal, then rallied nearly 20% as the M&A offer replaced a feared capital raise, and subsequently stayed pinned near $115 amid tender offer progress and Anito-cel BLA acceptance.
The schedule
- Thu1Oct
Assuming regulatory clearance and successful tender mechanics, the final key catalyst is the formal closing of the Gilead–Arcellx merger and cash-out of ACLX shareholders at $115.00 per share. By early October 2026, the market should know whether the transaction closes on schedule, with ACLX effectively trading as a cash proxy around $118.0 into the closing date. If Gilead consummates the acquisition as agreed, remaining shareholders realize the merger consideration and the stock should hold near $118.0 until delisting. In a tail-risk scenario where closing is delayed or the deal is terminated late in the process, ACLX could lose its M&A floor and re-rate sharply lower toward $70.00 as investors pivot back to the company’s standalone CAR-T pipeline risks, weak current revenues, and high cash-burn profile.
- Tue3Nov
- Sun8Nov
- Tue9Feb
- Sun9May
Past
- Sun9Aug
Actual outcome: Mixed
- Sat1Aug
Actual outcome: Mixed
The next major milestone is regulatory review of the Gilead–Arcellx acquisition under the Hart-Scott-Rodino (HSR) Act and other antitrust regimes. By early August 2026, the market should have clarity on whether the transaction receives routine clearance or faces extended scrutiny. If regulators grant timely clearance with standard conditions, ACLX should trade as a near-cash instrument at roughly $118.0, reflecting a negligible residual spread and the time value of money into closing. Conversely, if the FTC or other authorities signal concerns that threaten delay or possible litigation, merger-arb desks would begin to discount a partial break probability, driving ACLX down toward $118.00 as the stock re-rates closer to its pre-deal biotech value.
- Wed20May
Actual outcome: Bull · $115.07 at outcome
Arcellx shares remained pinned near Gilead's $115.00 per share tender offer price, indicating that the acquisition is proceeding smoothly. The tight deal spread reflects strong market confidence that tender participation and closing conditions are tracking as expected without significant break risk.
The first key near-term catalyst is Gilead Sciences’ ongoing tender offer for Arcellx at $115.00 per share. By around May 20, 2026, investors should have clearer visibility on tender participation, any extension of the offer period, and confirmation that closing conditions (including minimum shares tendered) are tracking as expected. A smooth extension or strong initial take-up would likely keep ACLX pinned close to the deal price near $116.5, while any signs of weak participation, revised terms, or language hinting at potential renegotiation could widen the deal spread and pull the stock back toward $116.50 as arb capital prices in higher break risk.
- Sun15Mar
Actual outcome: Bull · $114.77 at outcome
Instead of a dilutive capital raise, Arcellx was the subject of a $7.8 billion acquisition proposal by Gilead Sciences, which sought full control of the anito-cel oncology pipeline. This definitive M&A activity eliminated financing concerns and drove the stock price to $114.39, significantly exceeding the bull target of $102.00 as investors priced in the acquisition premium.
- Thu26Feb
Actual outcome: Bull · $114.05 at outcome
While Arcellx reported a slight EPS miss, the stock surged past its bull target due to the announcement that Gilead Sciences would acquire the company for $115 per share in a $7.8 billion all-cash deal. This acquisition premium drove a massive rally just prior to the earnings date, as the market prioritized the definitive merger agreement over the quarterly financial results.
